Blueprint Medicines BPMC reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Blueprint Medicines missed estimated earnings by 20.18%, reporting an EPS of $-2.68 versus an estimate of $-2.23.
Revenue was up $9.25 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.15 which was followed by a 0.7% increase in the share price the next day.
Here's a look at Blueprint Medicines's past performance:
|Quarter||Q1 2022||Q4 2021||Q3 2021||Q2 2021|
To track all earnings releases for Blueprint Medicines visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.